



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 13:04  
**Last Report Issued** 08/19/2016 14:40

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 3265B-POS  
**Patient ID** 3265B-POS  
**Chain** 15002164  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 15002164  
**Received** 08/19/2015 06:40

**Sample ID** 15002164-001  
**Matrix** Blood  
**Patient Name** 3265B-POS  
**Patient ID** 3265B-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**3265B Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

10-Hydroxycarbazepine	5.0	mcg/mL	0.50	
Synonym(s): Licarbazepine; Oxcarbazepine/Eslicarbazepine Acetate Metabolite				

Therapeutic serum range: 10 - 35 mcg/mL.

The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4.

This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepine in patients who have taken Eslicarbazepine Acetate (Aptiom®).

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.